InspireMD, Inc.
Close on Oct 19, 2026
- Market cap
- $37.25M
- P/E (TTM)
- –
- Dividend yield
- –
About InspireMD
Surgical & Medical Instruments & Apparatus, SIC 3841
InspireMD is a medical device company that develops and commercializes products for treating carotid artery disease and other vascular conditions. Its core proprietary offering centers on the MicroNet mesh sleeve paired with self-expanding nitinol stents to prevent embolic debris from causing strokes during and after carotid interventions. The company’s commercial portfolio includes the CGuard Carotid Embolic Prevention System, which holds European MDR CE Mark approval, and the CGuard Prime Carotid Stent System, which holds both U.S. FDA premarket approval and MDR CE Mark certification. In addition, the business is developing neuroprotection systems and expanding into transcarotid revascularization and acute stroke therapies. Its customers comprise physicians, healthcare facilities, and patients requiring carotid revascularization.
The company markets its products internationally across more than 30 countries outside the United States through independent distributors, alongside direct sales operations in the United States. Its global headquarters is located in Miami, Florida.
Summary of the business section of InspireMD's latest annual report, written by StockData.
Company profile
Company
- Legal name
- InspireMD, Inc.
- Founded
- 2008
- Headquarters
- Miami, FL
- Address
- 6303 Waterford District Drive, Suite 215 33126
- Phone
- (888) 776-6804
- Employees
- 127, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Kesselman & Kesselman, Tel-Aviv, Israel
Stock & identifiers
- Ticker
- NSPR
- Exchange
- Nasdaq
- Shares outstanding
- 46M, Aug 14, 2026
- Public float
- $60.93M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, May 10, 2021; 1-for-15 reverse, Apr 27, 2021; 1-for-50 reverse, May 13, 2019; 1-for-50 reverse, Apr 1, 2019; 1-for-35 reverse, Feb 13, 2018; 1-for-25 reverse, Nov 14, 2016; 1-for-25 reverse, Oct 10, 2016; 1-for-10 reverse, Oct 1, 2015; 1-for-10 reverse, Oct 1, 2015; 1-for-4 reverse, Dec 21, 2012; 1-for-4 reverse, Dec 19, 2012
- SEC CIK
- 1433607
- CUSIP
- 45779A846
- ISIN
- US45779A8466
- LEI
- 549300OQ16IJ5DIS5D30
- EIN
- 26-2123838
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Marvin Slosman | CEO and President, Director | 3,556,658 |
| Shane Thomas Gleason | Chief Commercial Officer | 1,053,882 |
| Michael A. Lawless | Chief Financial Officer | 691,695 |
| Andrea Tommasoli | Chief Operating Officer | 954,389 |
| Craig Shore | CFO and CAO | 1,112,460 |
| Patrick Verta | EVP Clinical/Medical Affairs | 311,532 |
| Gary S. Roubin | Director | 834,478 |
| Michael Berman | Director | 597,580 |
| Paul Stuka | Director | 1,091,575 |
| Scott R. Ward | Director | 237,096 |
| Raymond W. Cohen | Director | 92,417 |
| Danny L. Dearen | Director | 102,047 |
| Kathryn Arnold | Director | 303,087 |
| Thomas J. Kester | Director | 458,573 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Marvin Slosman | $3.10M | $1.32M | $1.83M | $207 | – |
| FY2024 Marvin Slosman | $3.30M | $2.36M | $1.58M | $306 | – |
| FY2023 Marvin Slosman | $3.22M | $5.87M | $1.45M | $327 | – |
| FY2022 Marvin Slosman | $696.81K | $115.27K | $492.25K | $17 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“of December 31, 2025, we had 127 full-time employees.”
Corporate history
Events identified from SEC filings